LAVA Therapeutics NV (LAVA Therapeutics NV) Gross Margin % : 56.37% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. LAVA Therapeutics NV's Gross Profit for the three months ended in Dec. 2023 was $0.20 Mil. LAVA Therapeutics NV's Revenue for the three months ended in Dec. 2023 was $0.35 Mil. Therefore, LAVA Therapeutics NV's Gross Margin % for the quarter that ended in Dec. 2023 was 56.37%.

The historical rank and industry rank for LAVA Therapeutics NV's Gross Margin % or its related term are showing as below:

LVTX' s Gross Margin % Range Over the Past 10 Years
Min: 48.56 Med: 48.56 Max: 48.56
Current: 48.56

During the past 5 years, the highest Gross Margin % of LAVA Therapeutics NV was 48.56%. The lowest was 48.56%. And the median was 48.56%.

LVTX's Gross Margin % is ranked worse than
62.31% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs LVTX: 48.56

LAVA Therapeutics NV had a gross margin of 56.37% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for LAVA Therapeutics NV was 0.00% per year.

LAVA Therapeutics NV Gross Margin % Historical Data

The historical data trend for LAVA Therapeutics NV's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV Gross Margin % Chart

LAVA Therapeutics NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

48.56

LAVA Therapeutics NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial												-	24.02	53.53	81.13	56.37

Competitive Comparison of LAVA Therapeutics NV's Gross Margin %

For the Biotechnology subindustry, LAVA Therapeutics NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LAVA Therapeutics NV's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's Gross Margin % distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's Gross Margin % falls into.

LAVA Therapeutics NV Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

LAVA Therapeutics NV's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	3.3	/	6.769
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(6.769 - 3.482)	/	6.769
	=	48.56 %

LAVA Therapeutics NV's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0.2	/	0.353
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.353 - 0.154)	/	0.353
	=	56.37 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

LAVA Therapeutics NV (NAS:LVTX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

LAVA Therapeutics NV had a gross margin of 56.37% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

LAVA Therapeutics NV Gross Margin % Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

4PKB:Germany

Address

Yalelaan 62, Utrecht, UT, NLD, 3584 CM

Website

https://www.lavatherapeutics.com

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.